Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Total Debt (2016 - 2021)

Historic Total Debt for Lineage Cell Therapeutics (LCTX) over the last 6 years, with Q1 2021 value amounting to $523000.0.

  • Lineage Cell Therapeutics' Total Debt changed N/A to $523000.0 in Q1 2021 from the same period last year, while for Mar 2021 it was $523000.0, marking a year-over-year change of. This contributed to the annual value of $523000.0 for FY2020, which is N/A changed from last year.
  • According to the latest figures from Q1 2021, Lineage Cell Therapeutics' Total Debt is $523000.0.
  • Over the past 5 years, Lineage Cell Therapeutics' Total Debt peaked at $523000.0 during Q2 2020, and registered a low of $18000.0 during Q4 2017.
  • For the 3-year period, Lineage Cell Therapeutics' Total Debt averaged around $293000.0, with its median value being $309000.0 (2017).
  • Data for Lineage Cell Therapeutics' Total Debt shows a peak YoY increase of 4508.67% (in 2017) and a maximum YoY decrease of 8500.0% (in 2017) over the last 5 years.
  • Over the past 3 years, Lineage Cell Therapeutics' Total Debt (Quarter) stood at $18000.0 in 2017, then soared by 2805.56% to $523000.0 in 2020, then changed by 0.0% to $523000.0 in 2021.
  • Its Total Debt stands at $523000.0 for Q1 2021, versus $523000.0 for Q4 2020 and $523000.0 for Q3 2020.